ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1366	National Cancer Institute	Html	en	Pruritus (PDQ®)–Health Professional Version	Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed.	pruritus 0.960641 second-generation antihistamines 0.585479 skin type 0.575303 atopic dermatitis 0.673145 skin surface 0.599366 worst pruritus 0.717892 atopic dermatitis population 0.574946 severe non-dermatological pruritus 0.718081 skin lipids 0.573883 Acad Dermatol Venereol 0.589376 primary dermatitis 0.600506 significant skin breakdown 0.59383 blood flow 0.584198 allergic skin reactions 0.594569 patients 0.575543 Dermatol Venereol Leprol 0.585578 placebo-controlled study 0.5912 radiation therapy 0.686843 Int J Dermatol 0.586614 Pain Symptom Manage 0.63754 healthy skin 0.593613 dry skin 0.639653 neuropathic pruritus 0.745005 et al. 0.592668	skin cleansing 0.573636 treatment 0.596222 skin reactions 0.599238 Oncol Nurs Forum 0.699339 skin dermatitis 0.603221 Opioid-induced Pruritus 0.704011 skin 0.704869 uraemic pruritus 0.705232 PUBMED Abstract 0.858232 Altered skin integrity 0.588103 Skin care 0.624412 Acta Derm Venereol 0.596823 pruritus relief 0.700635 itch 0.57584 allergic contact dermatitis 0.578553 skin hydration 0.574125 Clin Exp Dermatol 0.593566 skin change 0.583853 aggravates dry skin 0.598514 chronic idiopathic urticaria 0.638535 cholestatic pruritus 0.69774 Dermatol Ther 0.606265 intractable pruritus 0.703673 chronic pruritus 0.736276	CLICK HERE
1446	National Cancer Institute	Html	en	Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Patient Version	Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck.	cancer treatment 0.700679 oral mucositis pain 0.483396 tissue 0.465551 chemotherapy 0.631313 blood cell count 0.467595 mouth problems 0.466009 PDQ Oral Complications 0.468892 oral health exam 0.469677 mouth sores 0.537291 infections 0.470414 teeth 0.49264 neck radiation therapy 0.476468 high-dose chemotherapy 0.598756 cancer information summary 0.466904 oral mucositis 0.510415 stem cell transplant 0.72121 oral complications 0.763758 patients 0.61166 cancer patients 0.469036 radiation therapy patients 0.468456 dry mouth 0.687045 neck cancers 0.467921 radiation therapy 0.972855 Chronic dry mouth 0.472069 problems 0.532519	regular oral care 0.496586 oral care 0.520388 peroxide mouth rinses 0.475847 PDQ cancer information 0.50364 head 0.475462 mucous membranes 0.503677 mouth moist 0.469166 patient 0.472618 taste changes 0.470678 National Cancer Institute 0.465975 summary 0.488366 common oral complications 0.486948 Wipe mouth 0.467118 pain 0.536314 white blood cell 0.514465 tooth decay 0.48102 mouth guards 0.465834 gum disease 0.504216 salivary glands 0.547761 Managing Oral Complications 0.485092 PDQ summary 0.468583 mouth 0.82735 Different oral complications 0.468019 milder oral complications 0.467906	CLICK HERE
1494	National Cancer Institute	Html	en	Urethral Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of urethral cancer.	female urethral cancer 0.376591 major academic centers 0.28402 lymph node dissection 0.342065 urinary tract tumors 0.271423 annual incidence rates 0.28547 transitional cell carcinoma 0.949088 PDQ cancer information 0.378892 distal urethra 0.410475 commonly used tumor 0.321815 adjunctive radiation therapy 0.307204 cancer information summary 0.365437 definitive radiation 0.299917 2-cm tumor-free margin 0.279143 inguinal node dissection 0.345806 inguinal nodes 0.299311 anterior urethral carcinoma 0.459736 NCI PDQ cancer 0.276687 ipsilateral node dissection 0.459423 female urethra 0.380147 urethral catheter 0.320637 radiation therapy 0.634648 urethral cancer 0.577855 patient selection 0.261945 tumor margins 0.303956 single-center case series 0.440822	transitional cell mucosa 0.339607 ipsilateral palpable adenopathy 0.268507 urethral neoplasms 0.326534 2-cm margin proximal 0.288589 anterior vaginal wall 0.284136 node dissection 0.66141 anterior urethral cancers 0.391992 prostatic urethra 0.421315 proximal urethral cancers 0.428057 Intensity-modulated radiation therapy 0.317055 large tumors 0.285311 poor tumor control 0.307048 low-dose-rate iridium-192 sources 0.265079 frozen section confirmation 0.398049 End Results database 0.287533 inguinal adenopathy 0.28947 urethral cancers 0.578678 optimal surgical margin 0.277613 tumor 0.331558 stratified squamous epithelium 0.325971 pendulous urethra 0.304701 numerous periurethral glands 0.276798 inferior pubic rami 0.262509 low level 0.288208	CLICK HERE
1628	National Cancer Institute	Html	en	Urethral Cancer Treatment (PDQ®)–Patient Version	Urethral cancer occurs in men and women and can spread quickly to lymph nodes near the urethra. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for urethral cancer.	cancer treatment 0.362333 entire urethra 0.306444 lymph node dissection 0.557244 tissue 0.317299 body 0.398643 PDQ cancer information 0.410389 clinical trial search 0.378188 white blood cells 0.310278 bladder cancer 0.308764 clinical trials 0.773033 nearby lymph nodes 0.630197 cancer information summary 0.370147 clinical trial 0.499273 breast cancer prevention 0.294123 prostate gland 0.293841 patients 0.324988 invasive bladder cancer 0.301679 treatment clinical trial 0.300741 NCI PDQ cancer 0.319347 radiation therapy 0.651339 Urethral Cancer Treatment 0.356944 Treatment Editorial Board 0.30592 urethral cancer 0.837946 recurrent urethral cancer 0.334114	General information 0.298754 treatment 0.543719 new cancer treatments 0.306575 NCI-supported cancer 0.322826 cancer cells 0.450964 proximal urethral cancer 0.41852 urethral cancer spreads 0.344537 Cancer Information Service 0.306473 laser surgery 0.302658 patient 0.295185 treatment clinical trials 0.339398 anterior exenteration 0.294741 National Cancer Institute 0.373731 transurethral resection 0.314195 new treatment 0.34401 distal urethral cancer 0.388721 external radiation therapy 0.308401 cancer research process 0.298298 cancer clinical trials 0.402611 cancer information summaries 0.303961 comprehensive cancer information 0.304414 internal radiation therapy 0.302856 cancer 0.977674 standard treatment 0.307427	CLICK HERE
1674	National Cancer Institute	Html	en	Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.	Recurrent LCH 0.49021 cancer treatment 0.458844 childhood LCH lesions 0.545029 body 0.479436 high-risk multisystem LCH 0.563365 PDQ cancer information 0.430462 clinical trial search 0.417075 steroid therapy 0.417152 LCH lesions 0.646087 refractory childhood LCH 0.507141 Refractory LCH 0.491285 clinical trials 0.840496 LCH cells 0.723911 skin-only LCH 0.533026 cancer information summary 0.406099 clinical trial 0.546139 Langerhans cell histiocytosis 0.451003 patients 0.432765 LCH 0.976752 diagnose LCH 0.533565 lymph nodes 0.422079 treatment 0.665224 Progressive LCH 0.491974 BRAF gene 0.403636 LCH multisystem disease 0.521252	recurrent childhood LCH 0.508123 cancer cells 0.427036 pituitary gland 0.410888 childhood lch 0.600077 Adult LCH sections 0.511455 multisystem lch 0.599051 LCH trials 0.499932 LCH treatment 0.529717 treatment clinical trials 0.417639 National Cancer Institute 0.432317 effects cancer treatment 0.398781 small LCH lesions 0.540477 new treatment 0.409482 LCH bone lesions 0.547532 Adult LCH 0.522754 body systems 0.391142 LCH CNS 0.492291 bone marrow 0.4649 cancer clinical trials 0.44841 single-system lch 0.515862 progressive childhood LCH 0.507794 childhood LCH skin 0.522098 cancer 0.650545 information 0.432489	CLICK HERE
2042	National Cancer Institute	Html	es	Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga.	Cancer Inst Monogr 0.315885 Cancer Institute Surveillance 0.316979 urine cytology 0.306951 cuadro clínico 0.318123 Cancer Statistics Review 0.328453 transitional cell carcinoma 0.316775 Cancer registry problems 0.313029 Sin embargo 0.315264 American Cancer Society 0.340114 Hunt VB 0.306661 case-control study 0.305353 bladder cancer 0.978775 Young TB 0.311698 Bladder histological changes 0.316494 undergoing hematuria 0.308248 Malignant bladder tumors 0.31586 Can hematuria 0.308153 risk factors 0.306901 personas negras 0.307528 PDQ Exámenes 0.306867 patients with hematuria 0.310947 Messing EM 0.31983 Estados Unidos 0.311295 Natl Cancer Inst 0.403227 second cancers 0.320702	screening study using 0.305437 Bladder Cancer Group 0.328941 patients with 0.328907 neuropathic bladder 0.315447 SEER Cancer Statistics 0.328432 urinary tract 0.322774 Urol Clin North 0.310774 estadio t2+ 0.30573 detección casero 0.305242 Occup Med 0.308003 Cancer Facts 0.314556 bladder followed 0.315821 Noone AM 0.305423 National Cancer Institute 0.366947 Soloway MS 0.307825 Epidemiol Biomarkers Prev 0.327488 cell carcinoma 0.322375 asymptomatic microhematuria 0.311534 Clin North Am 0.316485 cell cytology screening 0.305294 bladder tumor 0.350128 invasive bladder 0.335021 bladder toxicity from 0.31599 transitional cell 0.318191	CLICK HERE
15481	National Cancer Institute	Html	en	Non-NIH Funded Investigators Submitting Data	null	large storage amounts 0.821627 Institutional Certification 0.889959 documents 0.389667 hughessk@mail.nih.gov. 0.612992 additional information/clarification 0.581935 Institutional Certification forms 0.830868 accession number 0.58702 scientific community 0.570468 Non-NIH funded investigators 0.91136 completeness 0.389773 DSPs 0.387872 data submission process 0.811324 GPA analyst registers 0.892324 expectations 0.444558 genomic data 0.66091 value 0.344731	DCB 0.394534 data submission formats 0.897528 NCI subcommittee 0.653863 dbGaP submission 0.557126 Basic Study Information 0.821294 Shannon Hughes 0.637978 steps 0.351008 Studies 0.345806 extramural GPAs 0.729046 GDC staff 0.659949 storage fee 0.567724 plans 0.351639 data submission 0.961251 GPA analyst 0.950832 consideration 0.365649 Jennifer Strasburger 0.670922	CLICK HERE
16297	National Cancer Institute	Html	en	Medicinal Mushrooms (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of medicinal mushrooms as a treatment for people with cancer.	G. lucidum products 0.573204 adjuvant chemotherapy 0.660268 PSK-treated group 0.523648 class I–negative patients 0.557926 control group 0.693917 humoral immune parameters 0.519217 Baseline immune parameters 0.519968 PDQ cancer information 0.546523 lung cancer 0.659292 investigators 0.524722 natural killer 0.558674 turkey tail 0.569981 innate immune cells 0.545469 advanced gastric cancer 0.572653 doxorubicin -based chemotherapy 0.54683 patients 0.832482 cancer patients 0.665826 G. lucidum 0.844684 gastric cancer patients 0.617385 PSK 0.985645 adjuvant therapy 0.585553 standard cancer treatments 0.5637 G. lucidum fruit 0.543411 cancer patient plasma 0.523542	radiation therapy 0.5502 lung cancer models 0.542252 medicinal mushrooms 0.540839 protein-bound PSK 0.737238 immune response pathways 0.537187 lung cancer cohort. 0.537885 PSK recipients 0.737199 PSK adjuvant immunotherapy 0.863333 PSK group 0.883506 advanced lung cancer 0.536376 G. lucidum polysaccharides 0.77527 advanced colorectal cancer 0.532494 National Cancer Institute 0.545709 5-year survival 0.544251 direct antitumor mechanisms 0.520707 lung cancer patients 0.596507 PSK patients 0.803579 adjuvant PSK 0.861863 gastric cancer 0.807983 G. lucidum enhance 0.535434 direct antitumor 0.521271 PSK treatment 0.759609 5-year survival rates 0.518116 MHC expression–negative patients 0.571654	CLICK HERE
16562	National Cancer Institute	Html	en	Screen to Save: NCI Colorectal Cancer Outreach and Screening Initiative	NCI Colorectal Cancer Outreach and Screening Initiative aims to increase colorectal cancer screening rates among ethnically and racially diverse and rural communities nationwide.	NCI-designated Cancer Centers 0.680452 country 0.523395 evidence-based resources 0.584437 education 0.537172 National Cancer Advisory 0.70446 Alaskan Natives 0.584304 recommendations 0.526636 overall assessment 0.573123 ethnically diverse communities 0.720461 local communities 0.586899 colorectal screening rates 0.853048 outreach activities 0.578711 colorectal cancer screening 0.850894 rural areas 0.584762 colorectal cancer 0.992617 Cancer Control National 0.675464 PACHE-funded community health 0.657281 community levels 0.588626 National Outreach Network 0.661026 Health Disparities Program 0.668335 women age 0.582977 Reduce Cancer Health 0.704459 American Indians 0.579831 Colorectal Cancer Awareness 0.761387	Cancer Moonshot 0.620655 Cancer Health Disparities 0.821429 NCI Center 0.608436 Blacks/African Americans 0.579578 Save initiative 0.611204 Cancer Health Equity 0.685373 NCI Colorectal Cancer 0.830393 Regional Coordinating Directors 0.639583 diverse partner network 0.664475 Blue Ribbon Panel 0.662084 rural communities 0.646304 Geographic Management 0.573805 community health educators 0.957975 outreach efforts 0.576306 Native Hawaiians 0.58859 screening resources 0.639461 Pacific Islanders 0.584476 evidence-based colorectal cancer 0.788139 key role 0.575779 colorectal screening behaviors 0.792179 NCI-approved colorectal cancer 0.776303 additional community engagements 0.645113 Screening Initiative 0.658551 information 0.537846	CLICK HERE
17290	National Cancer Institute	Html	es	Uso extraoficial de medicamentos en el tratamiento del cáncer	Conozca qué es el uso extraoficial o no indicado de medicamentos y el papel que desempeña en el tratamiento del cáncer.	régimen r-cvp 0.716896 régimen cmf 0.714486 régimen beacopp 0.710604 amplio uso 0.781419	Estados Unidos 0.77621 seguro médico 0.921249 siguientes razones 0.728265 régimen tac 0.710628	CLICK HERE